TY  - JOUR
AU  - Giardiello, Daniele
AU  - Steyerberg, Ewout W
AU  - Hauptmann, Michael
AU  - Adank, Muriel A
AU  - Akdeniz, Delal
AU  - Blomqvist, Carl
AU  - Bojesen, Stig E
AU  - Bolla, Manjeet K
AU  - Brinkhuis, Mariël
AU  - Chang-Claude, Jenny
AU  - Czene, Kamila
AU  - Devilee, Peter
AU  - Dunning, Alison M
AU  - Easton, Douglas F
AU  - Eccles, Diana M
AU  - Fasching, Peter A
AU  - Figueroa, Jonine
AU  - Flyger, Henrik
AU  - García-Closas, Montserrat
AU  - Haeberle, Lothar
AU  - Haiman, Christopher A
AU  - Hall, Per
AU  - Hamann, Ute
AU  - Hopper, John L
AU  - Jager, Agnes
AU  - Jakubowska, Anna
AU  - Jung, Audrey
AU  - Keeman, Renske
AU  - Kramer, Iris
AU  - Lambrechts, Diether
AU  - Le Marchand, Loic
AU  - Lindblom, Annika
AU  - Lubiński, Jan
AU  - Manoochehri, Mehdi
AU  - Mariani, Luigi
AU  - Nevanlinna, Heli
AU  - Oldenburg, Hester S A
AU  - Pelders, Saskia
AU  - Pharoah, Paul D P
AU  - Shah, Mitul
AU  - Siesling, Sabine
AU  - Smit, Vincent T H B M
AU  - Southey, Melissa C
AU  - Tapper, William J
AU  - Tollenaar, Rob A E M
AU  - van den Broek, Alexandra J
AU  - van Deurzen, Carolien H M
AU  - van Leeuwen, Flora E
AU  - van Ongeval, Chantal
AU  - Van't Veer, Laura J
AU  - Wang, Qin
AU  - Wendt, Camilla
AU  - Westenend, Pieter J
AU  - Hooning, Maartje J
AU  - Schmidt, Marjanka K
TI  - Prediction and clinical utility of a contralateral breast cancer risk model.
JO  - Breast cancer research
VL  - 21
IS  - 1
SN  - 1465-542X
CY  - London
PB  - BioMed Central
M1  - DKFZ-2020-00428
SP  - 144
PY  - 2019
AB  - Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making.We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B) since this information was available for only 6
LB  - PUB:(DE-HGF)16
C6  - pmid:31847907
C2  - pmc:PMC6918633
DO  - DOI:10.1186/s13058-019-1221-1
UR  - https://inrepo02.dkfz.de/record/153731
ER  -